Isis Granted $27M Payment from Biogen To Begin Phase 3 SMA ISIS-SMNRx Study
Isis Pharmaceuticals announced that it will initiate phase 3 clinical trials to study their investigational treatment for spinal muscular…
Articles by Ana de Barros, PhD
AveXis Launches Spinal Muscular Atrophy Clinical Trials Website
Dallas, Texas-based AveXis, Inc., a biotechnology company working to improve the quality of life of patients suffering from severe genetic…
AveXis to Present SMA Therapy Advances at Piper Jaffray Healthcare Conference
John Carbona, CEO of AveXis, along with Dr. Brian Kaspar have been invited to present the company’s latest developments at the 26th Annual Piper Jaffray…
Cure SMA Grants Breakthrough Award to Isis First-of-its-kind SMA Therapy
This year, Cure SMA granted the 2014 SMA Breakthrough Award to Isis Pharmaceuticals at the Cure SMA Gala of Hope, which took…
Santa Barbara Marathon and Gwendolyn Strong to Support SMA Next Saturday
Next Saturday, November, 8, Santa Barbara will host dozens of racers and walkers to raise both awareness and funds to support…
Isis Pharma Receives $5 Million Milestone Payment From GlaxoSmithKline
Isis Pharmaceuticals received a $5 million milestone payment from partner GlaxoSmithKline following news of its investigational drug ISIS-GSK5Rx being granted the development candidate designation. ISIS-GSK5Rx…
Organization “Families of SMA” Changes Name to “Cure SMA”
The organization “Families of SMA” which has been working since 1984 to help families suffering the burden of have…